Seres Therapeutics (MCRB) Receives a Buy from H.C. Wainwright


In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Seres Therapeutics (MCRB), with a price target of $8.00. The company’s shares closed last Monday at $3.10.

According to TipRanks.com, Bernardino is a 3-star analyst with an average return of 0.2% and a 32.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Aridis Pharmaceuticals, and Achieve Life Sciences.

Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $9.00, which is a 171.9% upside from current levels. In a report issued on March 16, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

Based on Seres Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.78 million. In comparison, last year the company had a GAAP net loss of $21.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts